Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488


Clinical Trial News

Erythropoietic protoporphyria: Phase III SCENESSE studies published

Clinuvel Pharmaceuticals Ltd has announced that results from its pivotal Phase III studies of SCENESSE® (afamelanotide 16mg) in the orphan genetic disorder erythropoietic protoporphyria (EPP)...

Cystic fibrosis gene therapy trial offers hope of treatment

A trial to test the safety and effectiveness of a therapy that replaces a faulty gene in the lungs of patients with cystic fibrosis has shown encouraging results.

Clinical trial: Melatonin offers hope for ADHD bedtime shut-eye

Sleep is vital to wellbeing, but children with attention deficit hyperactivity disorder (ADHD) often have trouble drifting off.

Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress...

Clinical investigation reviews approaches and outcomes of Africa-based HIV trials

A new article in Clinical Investigation highlights the learnings gleaned from monitoring several complex HIV clinical trials in Africa over a 15 year period.

Positive top-line results from stroke and TBI cohorts of PRISM II study announced

Avanir Pharmaceuticals, Inc. has announced top-line data from the PRISM II study showing that treatment with NUEDEXTA® was associated with a statistically significant reduction in symptoms of...

Pitt leads trial to reduce antibiotic overuse at post-acute and long-term care facilities

The University of Pittsburgh School of Medicine will be leading a $1.5 million national trial to examine methods to reduce unnecessary use of antibiotics in post-acute and long-term care...

Ruxolitinib is useful for long-term treatment of polycythemia vera

From the 20th Congress of the European Hematology Association, we report on evidence for ruxolitinib as a long-term polycythemia vera treatment.

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook